›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Guardant360 TissueNext™
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Guardant HealthType:
Laboratory Developed Test
Related tests:
Evidence Level:
Sensitive: B - Late Trials
[EML4-ALK variant 1-Non Small Cell Lung Cancer-lorlatinib]
Source:
Title:
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Published date:
05/26/2022
Excerpt:
Based on ctDNA, ORRs were generally higher in the lorlatinib vs crizotinib arm, reaching 80% and 72% for EML4-ALK v1 and v3, respectively, in the lorlatinib arm, and 50% and 74% in the crizotinib arm....Pts with untreated ALK+ advanced NSCLC had higher ORRs and potentially longer PFS across predefined biomarker subgroups when treated with lorlatinib compared with crizotinib in the phase 3 CROWN study.
DOI:
10.1200/JCO.2022.40.16_suppl.9070
Trial ID:
Evidence Level:
Sensitive: B - Late Trials
[EML4-ALK variant 3-Non Small Cell Lung Cancer-lorlatinib]
Source:
Title:
Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.
Published date:
05/26/2022
Excerpt:
Based on ctDNA, ORRs were generally higher in the lorlatinib vs crizotinib arm, reaching 80% and 72% for EML4-ALK v1 and v3, respectively, in the lorlatinib arm, and 50% and 74% in the crizotinib arm....Pts with untreated ALK+ advanced NSCLC had higher ORRs and potentially longer PFS across predefined biomarker subgroups when treated with lorlatinib compared with crizotinib in the phase 3 CROWN study.
DOI:
10.1200/JCO.2022.40.16_suppl.9070
Trial ID:
